Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference
May 19, 2025 08:00 ET | Source: Respira Therapeutics, Inc PALO ALTO,…
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements…
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and…
Preclinical insights into dosing for first-in-human in vivo liver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual Meeting
PRESS RELEASEPreclinical insights into dosing for first-in-human in vivo liver-directed gene therapy…
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational…
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure…
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week 2025
April 28, 2025 03:00 ET | Source: EnteroBiotix EnteroBiotix Announces Oral Presentation…
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no…
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohns and Colitis Congress
February 04, 2025 07:00 ET | Source: Shattuck Labs, Inc. AUSTIN, TX…
Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal…